A 52-year-old man with a 10-year history of type 2 diabetes mellitus presents with a 6-week history of depressed mood, fatigue, insomnia, and loss of appetite. He reports feeling 'empty inside' with no interest in his hobbies. His wife notes he has become increasingly irritable and withdrawn. He denies suicidal thoughts but expresses hopelessness about his future. Current medications include metformin and lisinopril. Physical examination is unremarkable. HbA1c is 8.2%, and thyroid function tests are normal. Which of the following is the MOST important consideration in selecting an antidepressant for this patient?

Explanation

## Antidepressant Selection in Comorbid Diabetes and Depression ### Clinical Context: Depression + Diabetes This patient has **Major Depressive Disorder** comorbid with **Type 2 Diabetes Mellitus** — a common and clinically significant combination [cite:Kaplan & Sadock 11e Ch 8]. **Key Point:** Depression occurs in 15–20% of diabetic patients and worsens glycemic control, increases cardiovascular risk, and reduces medication adherence. Antidepressant choice must balance psychiatric efficacy with metabolic safety. ### Metabolic Considerations in Antidepressant Selection | Antidepressant Class | Metabolic Effect | Glycemic Impact | Recommendation in Diabetes | |---------------------|------------------|-----------------|---------------------------| | **SSRI** (sertraline, escitalopram) | Minimal weight gain | Neutral or slight improvement | **Preferred first-line** | | **SNRI** (venlafaxine, duloxetine) | Minimal to mild weight gain | Neutral; duloxetine may help neuropathic pain | **Good alternative** | | **Tricyclic** (amitriptyline) | Significant weight gain | Worsens glycemic control | Avoid unless pain indication | | **Atypical** (mirtazapine) | Significant weight gain | Worsens glycemic control | Avoid | | **MAOI** | Variable | Unpredictable | Avoid (complex interactions) | **High-Yield:** SSRIs are the **safest and most evidence-based choice** in diabetic patients with depression because they: 1. Have minimal metabolic side effects 2. Do not worsen glycemic control 3. May slightly improve HbA1c through improved mood and adherence 4. Have excellent tolerability and safety profile ### Why This Patient Needs Metabolic Monitoring **Clinical Pearl:** Even with metabolically-neutral antidepressants, depression itself impairs glycemic control through: - Reduced medication adherence - Decreased physical activity - Altered eating patterns - Increased cortisol and inflammatory markers Therefore, **close monitoring of HbA1c and blood glucose** is essential regardless of antidepressant choice. ### Management Algorithm ```mermaid flowchart TD A[MDD + Type 2 DM]:::outcome --> B{Comorbid pain?}:::decision B -->|No pain| C[First-line: SSRI<br/>sertraline or escitalopram]:::action B -->|Diabetic neuropathy| D[Consider SNRI<br/>duloxetine preferred]:::action C --> E[Baseline HbA1c, glucose]:::action D --> E E --> F[Start antidepressant<br/>at standard dose]:::action F --> G[Reassess mood at 4 weeks<br/>Recheck HbA1c at 3 months]:::decision G -->|Improved mood<br/>Stable/improved HbA1c| H[Continue + monitor]:::action G -->|Poor response| I[Increase dose or<br/>switch agent]:::action ``` **Mnemonic:** **SAFE in Diabetes** — **S**SSRI, **A**void tricyclics/atypicals, **F**ocus on metabolic monitoring, **E**ncourage lifestyle adherence. ### Why Other Options Are Incorrect **Warning:** Do NOT fall for the hyponatremia trap (Option 1): - Hyponatremia from SSRIs is rare (~0.5–1% incidence) - It is NOT a reason to avoid SSRIs in diabetic patients - Monitoring baseline sodium is prudent, but SSRIs remain first-line **Tip:** Tricyclics (Option 2) cause significant weight gain and worsen glycemic control — they are contraindicated in diabetic depression unless there is a specific indication (e.g., neuropathic pain) that outweighs metabolic risk.